All targets
Target workspace
Cereblon
E3 ubiquitin ligase substrate receptor for IMiD immunomodulation.
Pathway & druggability
Protein degradation / IMiD mechanism
Druggability: Modulated by thalidomide analogs
Evidence behind this
Confidence score96%
Signal strength: HighLevel 1 (RCT + regulatory approval)
Evidence grade
Approved
Improved response rates and survival in combination regimens; REMS mandated.
Mechanism
Cereblon-dependent degradation of IKZF1/3 disrupts myeloma cell survival signaling.
clinical trialfda labelPhase III
Authoritative sources
AI-generated summary
Generated March 15, 2026Last verified June 20, 2026
Thalidomide plus dexamethasone demonstrated significant activity in relapsed myeloma, leading to FDA approval. REMS requirements reflect teratogenicity risk. Strong approved repurposing case.
Source papers
- Singhal S et al., 1999
- Dimopoulos MA et al., 2009
This summary is AI-assisted and human-reviewed. It does not constitute medical advice. Always consult authoritative sources and qualified professionals.